CO2023007684A2 - Una composición de rapamicina - Google Patents
Una composición de rapamicinaInfo
- Publication number
- CO2023007684A2 CO2023007684A2 CONC2023/0007684A CO2023007684A CO2023007684A2 CO 2023007684 A2 CO2023007684 A2 CO 2023007684A2 CO 2023007684 A CO2023007684 A CO 2023007684A CO 2023007684 A2 CO2023007684 A2 CO 2023007684A2
- Authority
- CO
- Colombia
- Prior art keywords
- rapamycin
- composition
- glyceryl
- monomyristin
- monolaurin
- Prior art date
Links
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 4
- 229960002930 sirolimus Drugs 0.000 title abstract 4
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 abstract 3
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000002144 chemical decomposition reaction Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940068939 glyceryl monolaurate Drugs 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La rapamicina es una sustancia terapéutica medicinalmente conocida. Un problema con la rapamicina es que es bastante inestable y propensa a la degradación química durante el almacenamiento. Esto puede conducir a que el medicamento se vuelva ‘bajo en fuerza’ durante su vida útil. Es un objeto de la invención avanzar al menos de alguna manera para abordar esto. La invención es una composición para tratamiento tópico, que comprende rapamicina como ingrediente activo; vehículo que comprende monolaurina, por ejemplo, como monolaurato de glicerilo y monomiristina, por ejemplo, como monomiristato de glicerilo; y agua como solvente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020277132A AU2020277132B1 (en) | 2020-11-24 | 2020-11-24 | A Rapamycin Composition |
| PCT/NZ2021/050194 WO2022114964A1 (en) | 2020-11-24 | 2021-11-04 | A rapamycin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023007684A2 true CO2023007684A2 (es) | 2023-07-21 |
Family
ID=78476632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0007684A CO2023007684A2 (es) | 2020-11-24 | 2023-06-13 | Una composición de rapamicina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240108606A1 (es) |
| EP (1) | EP4251151A1 (es) |
| JP (1) | JP2023550472A (es) |
| KR (1) | KR20230112677A (es) |
| CN (1) | CN116528905A (es) |
| AU (1) | AU2020277132B1 (es) |
| CA (1) | CA3196588A1 (es) |
| CO (1) | CO2023007684A2 (es) |
| CR (1) | CR20230284A (es) |
| EC (1) | ECSP23040785A (es) |
| GB (1) | GB2615048A (es) |
| IL (1) | IL302475A (es) |
| MA (1) | MA60467A1 (es) |
| MX (1) | MX2023005980A (es) |
| PE (1) | PE20240818A1 (es) |
| TW (1) | TW202237094A (es) |
| WO (1) | WO2022114964A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
| HUP1400075A2 (hu) * | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| BR112019002689A2 (pt) * | 2016-08-10 | 2019-05-14 | Univ Texas | terapia com rapamicina tópica |
| EP3829578A4 (en) * | 2018-08-30 | 2022-08-17 | Chemistryrx | COMPOSITIONS CONTAINING SIROLIMUS |
| EP3927319A1 (en) * | 2019-02-20 | 2021-12-29 | AI Therapeutics, Inc. | Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders |
-
2020
- 2020-11-24 AU AU2020277132A patent/AU2020277132B1/en active Active
-
2021
- 2021-10-19 TW TW110138730A patent/TW202237094A/zh unknown
- 2021-11-04 IL IL302475A patent/IL302475A/en unknown
- 2021-11-04 CA CA3196588A patent/CA3196588A1/en active Pending
- 2021-11-04 GB GB2306544.4A patent/GB2615048A/en active Pending
- 2021-11-04 MX MX2023005980A patent/MX2023005980A/es unknown
- 2021-11-04 KR KR1020237021011A patent/KR20230112677A/ko unknown
- 2021-11-04 CR CR20230284A patent/CR20230284A/es unknown
- 2021-11-04 JP JP2023530780A patent/JP2023550472A/ja active Pending
- 2021-11-04 WO PCT/NZ2021/050194 patent/WO2022114964A1/en active Application Filing
- 2021-11-04 EP EP21898774.1A patent/EP4251151A1/en active Pending
- 2021-11-04 US US18/038,409 patent/US20240108606A1/en active Pending
- 2021-11-04 MA MA60467A patent/MA60467A1/fr unknown
- 2021-11-04 PE PE2023001672A patent/PE20240818A1/es unknown
- 2021-11-04 CN CN202180077636.4A patent/CN116528905A/zh active Pending
-
2023
- 2023-06-01 EC ECSENADI202340785A patent/ECSP23040785A/es unknown
- 2023-06-13 CO CONC2023/0007684A patent/CO2023007684A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP23040785A (es) | 2023-07-31 |
| CN116528905A (zh) | 2023-08-01 |
| GB202306544D0 (en) | 2023-06-14 |
| US20240108606A1 (en) | 2024-04-04 |
| CA3196588A1 (en) | 2022-06-02 |
| WO2022114964A1 (en) | 2022-06-02 |
| IL302475A (en) | 2023-06-01 |
| GB2615048A (en) | 2023-07-26 |
| EP4251151A1 (en) | 2023-10-04 |
| PE20240818A1 (es) | 2024-04-18 |
| TW202237094A (zh) | 2022-10-01 |
| KR20230112677A (ko) | 2023-07-27 |
| CR20230284A (es) | 2023-08-07 |
| MX2023005980A (es) | 2023-06-07 |
| JP2023550472A (ja) | 2023-12-01 |
| MA60467A1 (fr) | 2023-08-31 |
| AU2020277132B1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080207537A1 (en) | Topical Ungual Formulations | |
| BR0313343A (pt) | Uso de uma mistura de agentes permeantes, soluções para aplicação ungueal e periungueal e uso de uma solução para aplicação ungueal e periungueal | |
| CR8163A (es) | Composicion farmaceutica que contiene un inhibidor de histona desacetilasa | |
| ECSP055938A (es) | Formulaciones farmaceuticas liquidas de palonosetron | |
| CR20120345A (es) | Derivados de 3-hidroxi-5-arilisotiazol novedosos | |
| AR035039A1 (es) | COMPOSICIONES QUE COMPRENDEN COMPONENTES TERAPEeTICAMENTE ACTIVOS DE SOLUBILIDAD Y BIODISPONIBILIDAD INCREMENTADA | |
| CL2023002383A1 (es) | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d | |
| SV2008002466A (es) | Oblea que contiene hormonas esteroides ref. p-sv-79.953/gh | |
| ES2734357T3 (es) | Composiciones antifúngicas para uso en el tratamiento de enfermedades de la piel | |
| US11786456B2 (en) | Transdermal delivery formulations | |
| AR082155A1 (es) | Formulacion antiseptica y desinfectante que tiene contenido de yodo reducido | |
| BR0312782A (pt) | Composição para o tratamento de manchas | |
| CO2023007684A2 (es) | Una composición de rapamicina | |
| BR112012015437A2 (pt) | composição tópica substancialmente anidra de armazenamento estável | |
| AR052882A1 (es) | Composicion antihelmintica | |
| CL2008001282A1 (es) | Composicion farmaceutica con actividad antimicrobiana que comprende un aminoacidos n halogenado y un agente antiinflamatorio; uso para prevenir o tratar una infeccion de tejidos, donde dicho tejido es ocular, nasal, seno nasal o dermico o una infeccion respiratoria. | |
| UY31059A1 (es) | Formulaciones de aminoacido n-halogenado | |
| ES2628707T3 (es) | Composición tópica potenciada | |
| AR046146A1 (es) | Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso | |
| CO2023002650A2 (es) | Formas farmacéuticas sólidas de palbociclib | |
| ES2200403T3 (es) | Tratamiento de los sintomas de la enfermedad de parkinson con un medio que contiene una sustancia que incrementa la concentracion de dopamina y un anestesico local del grupo de las anailidas. | |
| AR045178A1 (es) | Uso de un componente retinoide seleccionado entre el grupo formado por agentes retinoides activos, precursores de agentes retinoides activos y mezclas de los mismos, para preparar una composicion farmaceutica | |
| AR107212A1 (es) | Compuestos tópicos de matriz polimérica que comprenden una alta concentración de hialuronato de sodio biofermentado y sus usos | |
| ECSP056211A (es) | Composición y procedimiento de tratamiento del platanero y del bananero | |
| AR029718A1 (es) | Composicion farmaceutica a base de cocaetileno y su utilizacion para el tratamiento de la dependencia de las substancias psicoactivas |